Pharvaris NVFRA:9EN -1.76%28 FCF Yield % is -7.01 as of Jul. 11, 2026. GuruFocus rates FRA:9EN with a GF Score™ of 28/100. The stock has 3 warning signs investors should review. Among 1,408 Biotechnology companies, Pharvaris NV ranks better than 56.46% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Pharvaris NV FCF Yield % Related Terms
Pharvaris NV FCF Yield % Historical Data
* Premium members only.
The historical data trend for Pharvaris NV's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:9EN vs BHVN, NRIX, VCEL: FCF Yield % Comparison
For the Biotechnology subindustry, Pharvaris NV's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharvaris NV FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharvaris NV's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Pharvaris NV's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharvaris NV (FRA:9EN) has a FCF Yield % of -7.01 as of Jul. 11, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Pharvaris NV and its competitors. According to the industry distribution chart, Pharvaris NV ranks #613 out of 1408 companies in the Biotechnology industry, placing it in the top 43.5%.
Is Pharvaris NV's FCF Yield % too high?
Pharvaris NV's current FCF Yield % is -7.01. Based on the distribution chart, Pharvaris NV ranks #613 out of 1408 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Pharvaris NV has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Pharvaris NV's FCF Yield % compare to BHVN and NRIX?
According to the Biotechnology industry distribution chart, Pharvaris NV ranks #613 out of 1408 companies for FCF Yield %. This puts Pharvaris NV in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Pharvaris NV and its competitors. Pharvaris NV's current FCF Yield % is -7.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharvaris NV stock overvalued right now?
Pharvaris NV (FRA:9EN) has a current FCF Yield % of -7.01. The current FCF Yield % is -7.01. Pharvaris NV's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Pharvaris NV (FRA:9EN), the current FCF Yield % is -7.01 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
28GF Score
Get the complete analysis for FRA:9EN
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9EN has been successfully added to your 
